

AGG CGT CTC GTG GGC CAC AT) [(5' ACC AGG TGA GCC GAG GAC GCC  
AT)].

### REMARKS

Consideration and allowance of the subject application are respectfully requested.

Claims 1-15 are pending in the application.

The specification at page 7, lines 1-3 has been amended to include sequence identifiers (SEQ ID NO: 3, 4 and 5) for the disclosed sequences. No new matter has been added.

The specification at pages 11-43 has been amended to recite sequence identifiers for SEQ ID NO: 4 and 5. No new matter has been added.

Claims 6 and 15 have been amended to recite sequence identifiers. Claim 15 has also been amended to recite the sequence of SEQ ID NO: 3. Claims 1-8 and 10 have been amended to replace the improper "use" language with proper method language. Claims 5-8 and 10 have been amended to remove improper multiple dependencies. No new matter has been added. No claims have been amended to overcome prior art.

In accordance with 37 C.F.R. § 1.821(c), a paper copy of a substitute "Sequence Listing," new pages 11-42, is submitted herewith. It is respectfully requested that the substitute Sequence Listing be entered into the application. The substitute Sequence Listing does not contain new matter.

A computer readable copy of the substitute Sequence Listing is attached, in accordance with 37 C.F.R. § 1821(e). The computer readable substitute Sequence Listing does not contain new matter.

In accordance with 37 C.F.R. § 1.821(f), the contents of the paper copy and the computer readable copy of the Sequence Listing are the same.

The paper and electronic copies of the substitute Sequence Listing contain the following amendments. On page 11, the applicant <110>, reference No <130>, and the total number of sequence listings <160> have been amended as follows:

<110> Faustus Forschungs Cie. Translational Cancer Research GmbH

<130> PA32470US-01938

<160> 5

On pages 41-42, the new sequence listings for SEQ ID NO: 4 and 5 have been added as follows:

<210> 4

<211> 23

<212> DNA

<213> Artificial sequence

<220>

<223> Description of the artificial sequence: start-2-sense  
Synthetic oligonucleotide

<400> 4

atgtggccca cgagacgcct ggt 23

<210> 5

<211> 25

<212> DNA

<213> Artificial sequence

<220>

<223> Description of the artificial sequence: missense  
Synthetic oligonucleotide

<400> 5

agtactcagt aacgcctacg gtaag 25

No new matter has been added. New SEQ ID NO: 4 and 5 are disclosed on page 7, lines 1-3, of the translated application.

A copy of the Notice of Defective Response is attached.

It is respectfully submitted that the above-identified application complies with the Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures pursuant to 37 C.F.R. § 1.821-1.825.

U.S. Serial No. 09/700,906  
Page 8 of 8

Entry of substitute Sequence Listing and Amendment and a favorable action  
on the merits are respectfully requested.

Respectfully submitted,  
Manelli, Denison & Selter, PLLC

By 

Jeffrey S. Melcher

Reg. No.: 35,950

Tel. No.: (202) 778-1247

Fax. No.: (202) 887-0336

Customer No. 20736